Decreased peripheral benzodiazepine binding sites in platelets of neuroleptic-treated schizophrenics

https://doi.org/10.1016/0014-2999(86)90500-5Get rights and content

Abstract

A decrease of 30% was observed in the density of peripheral-type benzodiazepine binding sites in platelets of nine schizophrenics maintained on chronic neuroleptic treatment as compared to platelets of six untreated schizophrenics and 15 healty volunteers. The equilibrium dissociation constant for binding by [3H]PK 11195, which is a ligand specific for peripheral benzodiazepine binding sites, was similar in all three groups. The relevance of the reduction in peripheral-type benzodiazepine binding sites to central or peripheral side-effects induced by long-term neuroleptic treatment merits further investigation.

References (30)

  • I. Creese et al.

    Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

    Science

    (1976)
  • L.P. Davis et al.

    Peripheral benzodiazepine-binding sites in heart and their interaction with dipyridamole

    European J. Pharmacol.

    (1981)
  • E.B. De Souza et al.

    Peripheral-type benzodiazepine receptors in endocrine organs: autoradiographic localization in rat pituitary, adrenal and testis

    Endocrinology

    (1985)
  • Fares, F. and M. Gavish, Characterization of peripheral benzodiazepine-binding sites in human term placenta, Biochem....
  • S.E. File

    Pro- and anti-convulsant properties of PK 11195, a ligand for benzodiazepine-binding sites: development of tolerance

    Br. J. Pharmacol.

    (1984)
  • Cited by (62)

    • TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward

      2019, Pharmacology and Therapeutics
      Citation Excerpt :

      These studies may provide important information that may help the interpretation of current TSPO-PET findings. As far back as 1986, there were studies examining the levels of TSPO in platelets from schizophrenia subjects (Gavish et al., 1986; Weizman et al., 1986). Two different studies showed that the maximal number of [3H]PK11195 binding sites (Bmax) in platelets from untreated schizophrenia subjects did not differ from age-matched healthy controls.

    • Pharmacological characterization of senktide-induced tail whips

      2010, Neuropharmacology
      Citation Excerpt :

      However, antipsychotics may work indirectly at these receptors, as several reports show alterations in GABAA following chronic treatment with antipsychotics in rodents (Dean et al., 2001; Skilbeck et al., 2007). Furthermore, alterations in binding are also seen in schizophrenic patients, both in platelets (Gavish et al., 1986) and in post-mortem brain tissue (Benes et al., 1996; Deng and Huang, 2006; Newell et al., 2007; Pandey et al., 1997). It is unknown whether the pharmacologically induced tail whips seen in the present study actually represent aggressive and threat behaviors, as tail whips do in natural settings.

    • Effects of long-term low-dose hormone replacement therapy on the binding capacity of platelet peripheral-type benzodiazepine receptor in postmenopausal women

      2008, Psychoneuroendocrinology
      Citation Excerpt :

      All other chemicals were of reagent grade or better and obtained from normal commercial sources. The preparation of samples was performed as described previously (Gavish et al., 1986). Blood samples (10 ml) were obtained from women in two groups on the same day, collected into plastic tubes containing K2EDTA as the anticoagulant, and spun at 1000 rpm for 15 min at 4 °C.

    • Psychiatric disorders

      2007, Platelets
    View all citing articles on Scopus
    View full text